Demo Sign up Log In

Novavax Inc (NVAX)

R&D Expenses

$70.69M

Quarterly · Period ending: Jun 30, 2026 · USD

NVAX R&D Expenses

Latest reported$70.69Mperiod endingJun 30, 2026

Latest reported$70.69Mperiod endingJun 30, 2026

NVAX Quarterly R&D Expenses ($800.00K → $70.69M)

Quarterly R&D Expenses

High-resolution chart · PNG

NVAX r&d expenses history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Novavax Inc R&D Expenses — Quarterly (USD)
Period ending	R&D Expenses (USD)
Jun 30, 2001	3,837,000
Mar 31, 2001	2,592,000
Dec 31, 2000	2,797,000
Sep 30, 2000	2,924,000
Jun 30, 2000	2,113,000
Mar 31, 2000	1,524,000
Dec 31, 1999	1,200,000
Sep 30, 1999	1,100,000
Jun 30, 1999	600,000
Mar 31, 1999	500,000
Dec 31, 1998	1,300,000
Sep 30, 1998	900,000
Jun 30, 1998	700,000
Mar 31, 1998	600,000
Dec 31, 1997	900,000
Sep 30, 1997	700,000
Jun 30, 1997	800,000
Mar 31, 1997	600,000
Dec 31, 1996	1,200,000
Sep 30, 1996	800,000
Jun 30, 1996	900,000
Mar 31, 1996	800,000

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.